Oruka Therapeutics (ORKA) Competitors $10.09 -0.35 (-3.35%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$10.08 -0.01 (-0.10%) As of 04:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ORKA vs. VERA, TVTX, GPCR, MESO, EVO, INDV, OCUL, CALT, AMPH, and ARDXShould you be buying Oruka Therapeutics stock or one of its competitors? The main competitors of Oruka Therapeutics include Vera Therapeutics (VERA), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), Mesoblast (MESO), Evotec (EVO), Indivior (INDV), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Oruka Therapeutics vs. Vera Therapeutics Travere Therapeutics Structure Therapeutics Mesoblast Evotec Indivior Ocular Therapeutix Calliditas Therapeutics AB (publ) Amphastar Pharmaceuticals Ardelyx Vera Therapeutics (NASDAQ:VERA) and Oruka Therapeutics (NASDAQ:ORKA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations. Does the media refer more to VERA or ORKA? In the previous week, Vera Therapeutics had 4 more articles in the media than Oruka Therapeutics. MarketBeat recorded 14 mentions for Vera Therapeutics and 10 mentions for Oruka Therapeutics. Vera Therapeutics' average media sentiment score of 1.25 beat Oruka Therapeutics' score of 1.18 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, VERA or ORKA? Vera Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Oruka Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Does the MarketBeat Community believe in VERA or ORKA? Vera Therapeutics received 24 more outperform votes than Oruka Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Oruka Therapeutics an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformVera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Oruka TherapeuticsOutperform Votes17100.00% Underperform VotesNo Votes Is VERA or ORKA more profitable? Oruka Therapeutics' return on equity of -24.96% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vera TherapeuticsN/A -50.13% -39.50% Oruka Therapeutics N/A -24.96%-21.22% Which has better earnings and valuation, VERA or ORKA? Vera Therapeutics is trading at a lower price-to-earnings ratio than Oruka Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVera TherapeuticsN/AN/A-$95.99M-$2.75-8.64Oruka TherapeuticsN/AN/A-$5.34M-$5.79-1.74 Do institutionals and insiders hold more shares of VERA or ORKA? 99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by company insiders. Comparatively, 22.7% of Oruka Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts rate VERA or ORKA? Vera Therapeutics currently has a consensus target price of $64.67, suggesting a potential upside of 172.28%. Oruka Therapeutics has a consensus target price of $39.86, suggesting a potential upside of 295.02%. Given Oruka Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Oruka Therapeutics is more favorable than Vera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20Oruka Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 SummaryOruka Therapeutics beats Vera Therapeutics on 9 of the 16 factors compared between the two stocks. Get Oruka Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORKA vs. The Competition Export to ExcelMetricOruka TherapeuticsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$377.78M$2.60B$5.53B$7.93BDividend YieldN/A0.75%5.11%4.22%P/E Ratio-1.617.7322.5918.54Price / SalesN/A48.76401.35103.29Price / CashN/A15.7538.1834.62Price / BookN/A3.766.774.25Net Income-$5.34M-$65.73M$3.22B$248.18M7 Day PerformanceN/A-0.16%1.39%1.03%1 Month Performance7.11%-4.58%2.78%2.70%1 Year PerformanceN/A-12.29%15.85%4.05% Oruka Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORKAOruka Therapeutics3.154 of 5 stars$10.09-3.4%$39.86+295.0%N/A$377.78MN/A-1.61N/AAnalyst RevisionNews CoveragePositive NewsVERAVera Therapeutics2.9239 of 5 stars$21.11-0.8%$64.67+206.3%-43.9%$1.35BN/A-8.0940Upcoming EarningsPositive NewsTVTXTravere Therapeutics2.9274 of 5 stars$15.11+1.3%$32.08+112.3%+246.0%$1.34B$233.18M-3.69460Earnings ReportNews CoveragePositive NewsGPCRStructure Therapeutics2.2096 of 5 stars$23.10+6.2%$81.29+251.9%-30.5%$1.32BN/A-31.22136Upcoming EarningsNews CoverageHigh Trading VolumeMESOMesoblast1.9159 of 5 stars$10.28-4.1%$18.00+75.1%+65.6%$1.31B$5.67M0.0080Positive NewsEVOEvotec1.8567 of 5 stars$3.58-0.6%$5.93+65.7%-19.4%$1.27B$777.05M0.004,200Upcoming EarningsShort Interest ↓INDVIndivior3.205 of 5 stars$8.81-2.2%$15.00+70.3%-34.5%$1.21B$1.19B-25.171,164Short Interest ↑Positive NewsOCULOcular Therapeutix3.4801 of 5 stars$7.61+4.1%$16.38+115.2%+69.9%$1.21B$63.72M-5.77230Upcoming EarningsPositive NewsCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180AMPHAmphastar Pharmaceuticals4.4258 of 5 stars$23.50+0.6%$43.50+85.1%-43.3%$1.12B$731.97M7.831,620Upcoming EarningsPositive NewsARDXArdelyx4.5654 of 5 stars$4.56-5.4%$10.61+132.7%-17.2%$1.09B$333.62M-28.5090Earnings ReportNews CoveragePositive News Related Companies and Tools Related Companies VERA Competitors TVTX Competitors GPCR Competitors MESO Competitors EVO Competitors INDV Competitors OCUL Competitors CALT Competitors AMPH Competitors ARDX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORKA) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMassive dollar overhaul underway in D.C.?Trump's plan to save the U.S. Dollar The U.S. Dollar is crashing, and our reserve currency status is now in...Stansberry Research | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oruka Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oruka Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORKA Stock Free ORKA Stock Alerts